These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35331006)

  • 21. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma).
    Ogbonmide T; Rathore R; Rangrej SB; Hutchinson S; Lewis M; Ojilere S; Carvalho V; Kelly I
    Cureus; 2023 Mar; 15(3):e36197. PubMed ID: 37065340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry.
    Servais L; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Proud CM; Shieh PB; Tizzano EF; Quijano-Roy S; Desguerre I; Saito K; Faulkner E; Benguerba KM; Raju D; LaMarca N; Sun R; Anderson FA; Finkel RS
    J Neuromuscul Dis; 2024; 11(2):425-442. PubMed ID: 38250783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
    Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
    J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
    [No Abstract]   [Full Text] [Related]  

  • 25. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy.
    Kichula EA; Proud CM; Farrar MA; Kwon JM; Saito K; Desguerre I; McMillan HJ
    Muscle Nerve; 2021 Oct; 64(4):413-427. PubMed ID: 34196026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy.
    D'Silva AM; Holland S; Kariyawasam D; Herbert K; Barclay P; Cairns A; MacLennan SC; Ryan MM; Sampaio H; Smith N; Woodcock IR; Yiu EM; Alexander IE; Farrar MA
    Ann Clin Transl Neurol; 2022 Mar; 9(3):339-350. PubMed ID: 35170254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
    McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L
    Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Child Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA.
    Yazaki K; Sakuma S; Hikita N; Fujimaru R; Hamazaki T
    Neurology; 2022 May; 98(19):808-813. PubMed ID: 35351784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.
    Thomsen G; Burghes AHM; Hsieh C; Do J; Chu BTT; Perry S; Barkho B; Kaufmann P; Sproule DM; Feltner DE; Chung WK; McGovern VL; Hevner RF; Conces M; Pierson CR; Scoto M; Muntoni F; Mendell JR; Foust KD
    Nat Med; 2021 Oct; 27(10):1701-1711. PubMed ID: 34608334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio.
    Waldrop MA; Chagat S; Storey M; Meyer A; Iammarino M; Reash N; Alfano L; Lowes L; Noritz G; Prochoroff A; Rossman I; Ginsberg M; Mosher K; Broomall E; Bass N; Gushue C; Kotha K; Paul G; Shell R; Tsao CY; Mendell JR; Connolly AM
    Neuromuscul Disord; 2024 Jan; 34():41-48. PubMed ID: 38142474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy.
    Mendell JR; Al-Zaidy SA; Lehman KJ; McColly M; Lowes LP; Alfano LN; Reash NF; Iammarino MA; Church KR; Kleyn A; Meriggioli MN; Shell R
    JAMA Neurol; 2021 Jul; 78(7):834-841. PubMed ID: 33999158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy.
    Kotulska K; Fattal-Valevski A; Haberlova J
    Front Neurol; 2021; 12():726468. PubMed ID: 34721262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adeno-Associated Virus-Mediated Dorsal Root Ganglion Toxicity in the New Zealand White Rabbit.
    Tien E; Grubor B; Kirkland M; Chan SJ; van der Munnik N; Xu W; Henry K; Hamann S; Wei C; Lee WH; Gianni D; Brennecke A; Nambiar K; Chen J; Liu B; Shen S; Tremblay C; Plowey ED; Trapa P; Fikes J; Suh J; Morris D
    Toxicol Pathol; 2024 Jan; 52(1):35-54. PubMed ID: 38385340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy.
    Naveed A; Calderon H
    J Pediatr Pharmacol Ther; 2021; 26(5):437-444. PubMed ID: 34239394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children.
    Chencheri N; Alexander G; Nugud A; Majadas E; Salim H; Prudhomme K; DeJager N; Janardhanan VS; Elbashir H
    Muscle Nerve; 2023 Sep; 68(3):269-277. PubMed ID: 37392188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurofilament light chain and dorsal root ganglia injury after adeno-associated virus 9 gene therapy in nonhuman primates.
    Johnson EW; Sutherland JJ; Meseck E; McElroy C; Chand DH; Tukov FF; Hudry E; Penraat K
    Mol Ther Methods Clin Dev; 2023 Mar; 28():208-219. PubMed ID: 36700120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec.
    Tizzano EF; Quijano-Roy S; Servais L; Parsons JA; Aharoni S; Lakhotia A; Finkel RS;
    Eur J Paediatr Neurol; 2024 Nov; 53():18-24. PubMed ID: 39260228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating neurofilament light chain as a promising biomarker of AAV-induced dorsal root ganglia toxicity in nonclinical toxicology species.
    Fader KA; Pardo ID; Kovi RC; Somps CJ; Wang HH; Vaidya VS; Ramaiah SK; Sirivelu MP
    Mol Ther Methods Clin Dev; 2022 Jun; 25():264-277. PubMed ID: 35505662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.
    Hinderer C; Katz N; Buza EL; Dyer C; Goode T; Bell P; Richman LK; Wilson JM
    Hum Gene Ther; 2018 Mar; 29(3):285-298. PubMed ID: 29378426
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.